Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$311.04 - $363.55 $1,555 - $1,817
-5 Closed
0 $0
Q4 2023

Feb 07, 2024

BUY
$214.88 - $256.94 $429 - $513
2 Added 66.67%
5 $1,000
Q3 2023

Oct 25, 2023

BUY
$211.82 - $248.24 $635 - $744
3 New
3 $0
Q2 2023

Aug 10, 2023

BUY
$205.19 - $232.99 $0 - $0
0 New
0 $0
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $0 - $0
0 New
0 $0
Q4 2022

Jan 30, 2023

SELL
$205.95 - $280.43 $823 - $1,121
-4 Closed
0 $0
Q3 2022

Nov 15, 2022

SELL
$203.3 - $244.17 $28,462 - $34,183
-140 Reduced 97.22%
4 $1,000
Q2 2022

Aug 09, 2022

SELL
$174.81 - $241.14 $1,223 - $1,687
-7 Reduced 4.64%
144 $34,000
Q1 2022

May 09, 2022

BUY
$166.16 - $213.96 $166 - $213
1 Added 0.67%
151 $27,000
Q4 2021

Feb 07, 2022

SELL
$184.32 - $216.08 $737 - $864
-4 Reduced 2.6%
150 $32,000
Q3 2021

Nov 09, 2021

SELL
$179.86 - $214.88 $359 - $429
-2 Reduced 1.28%
154 $28,000
Q2 2021

Aug 13, 2021

SELL
$170.47 - $211.93 $340 - $423
-2 Reduced 1.27%
156 $27,000
Q1 2021

May 13, 2021

SELL
$153.94 - $174.85 $2,001 - $2,273
-13 Reduced 7.6%
158 $26,000
Q4 2020

Feb 02, 2021

SELL
$101.87 - $151.79 $509 - $758
-5 Reduced 2.84%
171 $26,000
Q3 2020

Nov 13, 2020

BUY
$99.9 - $121.13 $17,582 - $21,318
176 New
176 $18,000
Q2 2020

Aug 13, 2020

BUY
$92.74 - $125.82 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020

SELL
$79.39 - $115.35 $3,413 - $4,960
-43 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$74.85 - $85.99 $4,790 - $5,503
-64 Reduced 59.81%
43 $3,000
Q2 2019

Aug 13, 2019

BUY
$76.06 - $120.81 $1,825 - $2,899
24 Added 28.92%
107 $8,000
Q1 2019

May 15, 2019

BUY
$107.15 - $126.84 $1,178 - $1,395
11 Added 15.28%
83 $9,000
Q4 2018

Feb 14, 2019

BUY
$101.4 - $128.73 $3,143 - $3,990
31 Added 75.61%
72 $7,000
Q3 2018

Nov 13, 2018

BUY
$113.81 - $129.46 $4,666 - $5,307
41 New
41 $5,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.